See more : Minerals Technologies Inc. (MTX) Income Statement Analysis – Financial Results
Complete financial analysis of Smith & Nephew plc (SNN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Smith & Nephew plc, a leading company in the Medical – Devices industry within the Healthcare sector.
- Saumya Consultants Limited (SAUMYA.BO) Income Statement Analysis – Financial Results
- Costain Group PLC (CSGQF) Income Statement Analysis – Financial Results
- Global Kids Company Corp. (6189.T) Income Statement Analysis – Financial Results
- Qingdao Footwear, Inc. (QING) Income Statement Analysis – Financial Results
- Bénéteau S.A. (BEN.PA) Income Statement Analysis – Financial Results
Smith & Nephew plc (SNN)
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 5.55B | 5.22B | 5.21B | 4.56B | 5.14B | 4.90B | 4.77B | 4.67B | 4.63B | 4.62B | 4.35B | 4.14B | 4.27B | 3.96B | 3.77B | 3.80B | 3.37B | 2.78B | 2.55B | 2.39B | 2.11B | 1.79B | 1.58B | 1.69B | 1.81B | 1.75B | 1.73B | 1.83B | 1.59B | 1.51B | 1.40B | 1.30B | 1.48B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
Cost of Revenue | 1.73B | 1.52B | 1.51B | 1.38B | 1.33B | 1.30B | 1.25B | 1.27B | 1.14B | 1.13B | 1.08B | 1.07B | 1.14B | 1.03B | 1.03B | 1.08B | 994.00M | 769.00M | 701.00M | 642.17M | 616.25M | 531.63M | 509.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 3.82B | 3.70B | 3.70B | 3.18B | 3.81B | 3.61B | 3.52B | 3.40B | 3.49B | 3.49B | 3.27B | 3.07B | 3.13B | 2.93B | 2.74B | 2.72B | 2.38B | 2.01B | 1.85B | 1.75B | 1.49B | 1.26B | 1.07B | 1.69B | 1.81B | 1.75B | 1.73B | 1.83B | 1.59B | 1.51B | 1.40B | 1.30B | 1.48B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
Gross Profit Ratio | 68.82% | 70.85% | 70.95% | 69.71% | 74.09% | 73.53% | 73.81% | 72.76% | 75.33% | 75.59% | 75.11% | 74.14% | 73.30% | 73.98% | 72.69% | 71.67% | 70.50% | 72.33% | 72.53% | 73.18% | 70.73% | 70.26% | 67.63% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 299.00M | 442.00M | 397.00M | 307.00M | 292.00M | 246.00M | 223.00M | 230.00M | 222.00M | 235.00M | 231.00M | 171.00M | 167.00M | 151.00M | 155.00M | 152.00M | 142.00M | 120.00M | 122.00M | 127.36M | 119.29M | 98.79M | 74.12M | 69.30M | 73.12M | 71.54M | 69.27M | 70.73M | 45.43M | 45.34M | 43.04M | 36.86M | 37.80M | 32.79M | 22.79M | 23.79M | 0.00 | 0.00 | 0.00 |
General & Administrative | 384.00M | 2.88B | 2.72B | 2.56B | 2.69B | 2.50B | 2.36B | 2.37B | 2.64B | 0.00 | 2.06B | 2.05B | 2.10B | 1.86B | 1.86B | 1.94B | 1.74B | 1.32B | 689.00M | 1.15B | 975.54M | 872.14M | 750.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 2.22B | 2.07B | 2.01B | 1.77B | 1.91B | 1.82B | 1.78B | 1.71B | 1.74B | 0.00 | 91.00M | 1.44B | 0.00 | 0.00 | 0.00 | 1.80B | 1.53B | 1.32B | 1.21B | 0.00 | 853.57M | -307.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 2.60B | 2.70B | 2.64B | 2.44B | 2.53B | 2.38B | 2.42B | 2.26B | 2.52B | 2.32B | 2.15B | 2.05B | 2.10B | 1.86B | 1.86B | 1.80B | 1.53B | 1.32B | 1.21B | 1.15B | 975.54M | 872.14M | 750.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Expenses | 493.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00M | 0.00 | 0.00 | -4.00M | 0.00 | -87.50M | -58.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 3.39B | 3.39B | 3.04B | 2.88B | 3.01B | 2.77B | 2.59B | 2.29B | 2.89B | 2.75B | 2.47B | 2.22B | 2.27B | 2.01B | 2.02B | 2.08B | 1.77B | 1.45B | 1.35B | 1.28B | 1.09B | 1.52B | 839.35M | 1.60B | 1.65B | 1.51B | 1.45B | 1.52B | 1.33B | 1.02B | 1.18B | 1.10B | 1.12B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
Cost & Expenses | 5.12B | 4.91B | 4.55B | 4.26B | 4.34B | 4.07B | 3.84B | 3.56B | 4.04B | 3.88B | 3.55B | 3.29B | 3.41B | 3.04B | 3.05B | 3.16B | 2.76B | 2.22B | 2.05B | 1.92B | 1.71B | 1.52B | 1.35B | 1.60B | 1.65B | 1.51B | 1.45B | 1.52B | 1.33B | 1.02B | 1.18B | 1.10B | 1.12B | 1.41B | 1.14B | 1.08B | 1.02B | 709.77M | 609.40M |
Interest Income | 34.00M | 66.00M | 74.00M | 56.00M | 55.00M | 51.00M | 51.00M | 46.00M | 38.00M | 22.00M | 4.00M | 11.00M | 4.00M | 3.00M | 2.00M | 5.00M | 10.00M | 19.00M | 27.00M | 32.22M | 19.64M | 0.00 | 0.00 | 6.57M | 16.66M | 13.45M | 14.22M | 7.36M | 10.35M | 17.98M | 26.33M | 37.01M | 49.59M | 53.62M | 30.81M | 21.98M | 27.17M | 18.04M | 17.14M |
Interest Expense | 139.00M | 80.00M | 80.00M | 62.00M | 65.00M | 59.00M | 57.00M | 52.00M | 50.00M | 45.00M | 21.00M | 9.00M | 12.00M | 18.00M | 42.00M | 71.00M | 40.00M | 9.00M | 18.00M | 23.81M | 10.71M | 20.46M | 0.00 | 17.03M | 11.16M | 16.27M | 20.66M | 17.13M | 17.46M | 16.88M | 35.50M | 40.65M | 65.30M | 84.49M | 55.04M | 47.03M | 44.97M | 24.10M | 26.22M |
Depreciation & Amortization | 527.00M | 548.00M | 563.00M | 545.00M | 496.00M | 427.00M | 435.00M | 415.00M | 445.00M | 351.00M | 297.00M | 324.00M | 306.00M | 288.00M | 312.00M | 287.00M | 237.00M | 169.00M | 180.00M | 137.33M | 143.21M | 152.05M | 87.81M | 79.16M | 87.84M | 82.00M | 67.45M | 72.78M | 61.19M | 57.22M | 53.25M | 49.29M | 52.95M | 51.12M | 36.75M | 33.34M | 35.60M | 24.69M | 20.17M |
EBITDA | 979.00M | 1.00B | 1.22B | 839.00M | 1.43B | 1.29B | 1.39B | 1.53B | 1.07B | 1.28B | 1.19B | 1.18B | 1.16B | 1.25B | 1.01B | 936.00M | 721.00M | 703.00M | 591.00M | 250.00M | 265.00M | 362.43M | 313.67M | 409.69M | 361.29M | 305.02M | 340.04M | 395.93M | 351.84M | 65.51M | 332.67M | 324.42M | 249.80M | 390.42M | 314.83M | 295.16M | 279.73M | 179.18M | 148.10M |
EBITDA Ratio | 17.64% | 21.36% | 22.60% | 20.33% | 27.77% | 28.61% | 27.49% | 28.42% | 25.68% | 27.79% | 27.24% | 28.57% | 27.31% | 30.57% | 27.55% | 24.63% | 25.59% | 26.92% | 27.82% | 26.58% | 26.29% | 24.52% | 20.01% | 21.99% | 21.06% | 19.96% | 20.41% | 21.68% | 22.29% | 22.72% | 22.60% | 23.50% | 24.48% | 27.74% | 27.63% | 27.40% | 27.32% | 25.24% | 24.30% |
Operating Income | 425.00M | 665.00M | 712.00M | 433.00M | 981.00M | 976.00M | 875.00M | 912.00M | 745.00M | 932.00M | 888.00M | 846.00M | 862.00M | 920.00M | 723.00M | 630.00M | 493.00M | 537.00M | 422.00M | 317.06M | 321.07M | 242.73M | 225.86M | 214.78M | 178.43M | 209.98M | 269.29M | 311.50M | 253.11M | 215.12M | 238.60M | 214.92M | 252.61M | 339.30M | 278.08M | 261.82M | 244.13M | 154.49M | 127.93M |
Operating Income Ratio | 7.66% | 12.75% | 13.66% | 9.50% | 19.09% | 19.90% | 18.36% | 19.53% | 16.08% | 20.19% | 20.41% | 20.45% | 20.19% | 23.22% | 19.17% | 16.57% | 14.63% | 19.32% | 16.54% | 13.24% | 15.25% | 13.58% | 14.34% | 12.67% | 9.85% | 12.01% | 15.54% | 17.01% | 15.96% | 14.26% | 17.00% | 16.52% | 17.05% | 24.11% | 24.41% | 24.30% | 23.85% | 21.77% | 20.99% |
Total Other Income/Expenses | -135.00M | -215.00M | -7.00M | -49.00M | -72.00M | -82.00M | -55.00M | 150.00M | -69.00M | -35.00M | -8.00M | 242.00M | -14.00M | -25.00M | -53.00M | -66.00M | -24.00M | 35.00M | -54.00M | 2.00M | -9.00M | 43.83M | -15.58M | -10.47M | 116.15M | 13.28M | -17.36M | -5.48M | 20.09M | -223.72M | 5.33M | 19.57M | -121.07M | -84.49M | -55.04M | -47.03M | -44.97M | -24.10M | -26.22M |
Income Before Tax | 290.00M | 235.00M | 586.00M | 246.00M | 743.00M | 781.00M | 879.00M | 1.06B | 559.00M | 714.00M | 802.00M | 1.10B | 848.00M | 895.00M | 670.00M | 564.00M | 469.00M | 550.00M | 428.00M | 345.83M | 410.89M | 290.73M | 210.28M | 396.10M | 294.58M | 223.26M | 251.93M | 306.02M | 273.19M | -8.60M | 243.92M | 234.48M | 131.54M | 254.81M | 223.04M | 214.79M | 199.16M | 130.39M | 101.71M |
Income Before Tax Ratio | 5.23% | 4.51% | 11.24% | 5.39% | 14.46% | 15.93% | 18.45% | 22.75% | 12.06% | 15.46% | 18.43% | 26.59% | 19.86% | 22.59% | 17.76% | 14.84% | 13.92% | 19.79% | 16.77% | 14.44% | 19.52% | 16.26% | 13.35% | 23.37% | 16.26% | 12.77% | 14.54% | 16.71% | 17.23% | -0.57% | 17.38% | 18.02% | 8.88% | 18.10% | 19.57% | 19.94% | 19.45% | 18.37% | 16.69% |
Income Tax Expense | 27.00M | 12.00M | 62.00M | 202.00M | 143.00M | 118.00M | 112.00M | 278.00M | 149.00M | 213.00M | 246.00M | 371.00M | 266.00M | 280.00M | 198.00M | 187.00M | 153.00M | 156.00M | 126.00M | 85.55M | 146.43M | 105.98M | 93.20M | 86.18M | 125.05M | 67.72M | 63.98M | 99.33M | 98.89M | 75.67M | 83.13M | 67.95M | 43.79M | 65.01M | 59.53M | 64.33M | 58.64M | 41.10M | 33.14M |
Net Income | 263.00M | 223.00M | 524.00M | 448.00M | 600.00M | 663.00M | 767.00M | 784.00M | 410.00M | 501.00M | 556.00M | 729.00M | 582.00M | 615.00M | 472.00M | 377.00M | 316.00M | 745.00M | 333.00M | 290.01M | 264.46M | 184.75M | 188.72M | 309.92M | 169.54M | 155.53M | 187.96M | 206.70M | 174.30M | -84.27M | 160.79M | 155.92M | 74.66M | 143.13M | 147.63M | 145.24M | 140.52M | 89.29M | 68.43M |
Net Income Ratio | 4.74% | 4.28% | 10.05% | 9.82% | 11.68% | 13.52% | 16.10% | 16.79% | 8.85% | 10.85% | 12.78% | 17.62% | 13.63% | 15.52% | 12.51% | 9.92% | 9.38% | 26.81% | 13.05% | 12.11% | 12.56% | 10.33% | 11.98% | 18.29% | 9.36% | 8.90% | 10.85% | 11.29% | 10.99% | -5.59% | 11.46% | 11.99% | 5.04% | 10.17% | 12.96% | 13.48% | 13.73% | 12.58% | 11.23% |
EPS | 0.60 | 0.51 | 1.20 | 1.02 | 1.37 | 0.76 | 0.88 | 0.88 | 0.46 | 0.56 | 0.61 | 1.63 | 1.31 | 1.39 | 1.07 | 0.85 | 0.68 | 1.58 | 0.71 | 0.57 | 0.57 | 0.20 | 0.20 | 0.30 | 0.18 | 0.17 | 0.21 | 0.23 | 0.19 | -0.09 | 0.19 | 0.19 | 0.09 | 0.18 | 0.18 | 0.18 | 0.18 | 0.16 | 0.20 |
EPS Diluted | 0.60 | 0.51 | 1.19 | 1.02 | 1.37 | 0.76 | 0.88 | 0.88 | 0.46 | 0.56 | 0.61 | 1.62 | 1.30 | 1.38 | 1.07 | 0.85 | 0.68 | 1.58 | 0.71 | 0.56 | 0.56 | 0.19 | 0.20 | 0.30 | 0.18 | 0.17 | 0.21 | 0.23 | 0.19 | -0.09 | 0.19 | 0.19 | 0.09 | 0.18 | 0.18 | 0.18 | 0.18 | 0.16 | 0.20 |
Weighted Avg Shares Out | 435.50M | 436.00M | 438.50M | 437.50M | 437.00M | 875.83M | 874.57M | 892.94M | 899.00M | 899.46M | 905.54M | 448.50M | 445.50M | 444.00M | 441.95M | 443.00M | 461.50M | 470.50M | 465.00M | 467.50M | 465.00M | 925.68M | 921.00M | 1.03B | 801.94M | 908.18M | 908.20M | 904.11M | 896.75M | 889.38M | 842.75M | 823.11M | 817.38M | 811.65M | 802.25M | 791.20M | 778.11M | 551.88M | 333.83M |
Weighted Avg Shares Out (Dil) | 436.88M | 436.50M | 439.00M | 438.50M | 438.50M | 876.00M | 875.00M | 893.00M | 899.00M | 899.00M | 906.00M | 450.50M | 447.50M | 444.50M | 442.78M | 445.00M | 464.00M | 472.00M | 471.50M | 470.50M | 468.00M | 954.24M | 929.55M | 1.03B | 803.65M | 910.35M | 910.66M | 904.11M | 896.75M | 889.38M | 842.75M | 823.11M | 817.38M | 811.65M | 802.25M | 791.20M | 778.11M | 551.88M | 333.83M |
National Bank of Canada FI Has $53,000 Stake in Smith & Nephew plc (NYSE:SNN)
Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript
Smith & Nephew tops Footsie after bullish sales update
U.K. Top 40 Quality Dividend Stocks: Q2 2024
Smith+Nephew (SNN) Expands in Australia With New Alliance
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
Source: https://incomestatements.info
Category: Stock Reports